Allegheny Health Network Research Institute

Pittsburgh, Pennsylvania 15224

2 studies enrolling now · 15 studies all time

What they study most

Acid Reflux, Acute DVT of Lower Extremity, Acute Ischemic Stroke, BD Prevue II for Peripheral Intravenous Catheter Placement, COVID-19, Cancer, Cardiac Disease, Cardiovascular Diseases, Chronic DVT of Lower Extremity, Chronic Heart Failure With Preserved Systolic Function, DVT, Deep Vein Thrombosis Leg

Studies at this site

• RevCore for In Stent Thrombosis — Recruiting now
• Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial — Recruiting now
• The PEERLESS II Study — Running, not enrolling
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Running, not enrolling
• An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux — Stopped early
• Harm Reduction in HIV Primary Care for PLWH Who Use Drugs — Running, not enrolling
• BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study — Completed
• ClotTriever Outcomes (CLOUT) Registry — Completed
• Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients) — Running, not enrolling
• Repository of Phase Signals for Pulmonary Hypertension Algorithm Development — Status unconfirmed
• The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis — Completed
• CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients — Stopped early
• Dapagliflozin in PRESERVED Ejection Fraction Heart Failure — Completed
• Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) — Completed
• Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer — Completed